Trial Profile

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary) ; Poly ICLC (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man
Acronyms HAITEN-ICI

Most Recent Events

29 Sep 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health
19 Sep 2024 Status changed from not yet recruiting to withdrawn prior to enrolment, because funding of this trial was discontinued.
26 Apr 2024 Planned primary completion date changed from 10 Mar 2026 to 22 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com